Related Experiment Video
Updated: Jul 3, 2026

Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
Published on: April 17, 2026
Targeted therapy for cancer using PARP inhibitors
Christopher J Lord1, Alan Ashworth
1The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, Fulham Road, London, UK. Chris.Lord@icr.ac.uk
Abstract:
Poly (ADP-ribose) Polymerase (PARP) has a well-established role in DNA repair processes, and small molecule inhibitors of PARP have been developed as chemotherapy sensitisers for the treatment of cancer. The subsequent demonstration that PARP inhibition is selective for BRCA1 or BRCA2 deficiency suggests that PARP inhibitors may be particularly useful for the treatment of cancer with BRCA mutations. This would represent one of the first clinically implemented examples of a synthetic lethal approach for cancer treatment. However, there are still unanswered questions surrounding PARP inhibitors, namely the levels of specificity and potency that are required to elicit BRCA selectivity. The recent identification of mechanisms of cellular resistance to PARP inhibitors may provide indications as to how these drugs may be best used in the clinic.
Insights
Poly (ADP-ribose) Polymerase (PARP) inhibitors show promise as cancer treatments, particularly for BRCA-mutated cancers, by exploiting synthetic lethality. Further research is needed to optimize their specificity and potency for clinical use.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Poly (ADP-ribose) Polymerase (PARP) enzymes are crucial for DNA repair.
- Small molecule PARP inhibitors are developed as chemotherapy sensitizers.
- PARP inhibition demonstrates selectivity for cancers with BRCA1/BRCA2 deficiencies.
Purpose of the Study:
- To explore the potential of PARP inhibitors in treating BRCA-mutated cancers.
- To investigate the synthetic lethal approach for cancer therapy.
- To address unanswered questions regarding PARP inhibitor specificity and potency.
Main Methods:
- Review of established roles of PARP in DNA repair.
- Analysis of studies demonstrating PARP inhibitor selectivity for BRCA deficiency.
- Examination of emerging mechanisms of cellular resistance to PARP inhibitors.
Main Results:
- PARP inhibitors show potential as a targeted therapy for BRCA-mutated cancers.
- This represents a clinically relevant application of synthetic lethality.
- Understanding resistance mechanisms is key to optimizing clinical application.
Conclusions:
- PARP inhibitors offer a promising synthetic lethal strategy for BRCA-mutated cancers.
- Further research is required to define optimal PARP inhibitor specificity and potency.
- Investigating resistance mechanisms will guide effective clinical use of PARP inhibitors.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

